Markel Group Inc. Acquires 3,000 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Markel Group Inc. grew its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 5.4% in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 58,726 shares of the medical research company’s stock after buying an additional 3,000 shares during the period. Markel Group Inc.’s holdings in IQVIA were worth $12,417,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also recently made changes to their positions in the company. Benjamin F. Edwards & Company Inc. raised its position in IQVIA by 119.0% during the fourth quarter. Benjamin F. Edwards & Company Inc. now owns 2,212 shares of the medical research company’s stock valued at $511,000 after purchasing an additional 1,202 shares during the period. 9258 Wealth Management LLC raised its holdings in IQVIA by 35.9% during the 4th quarter. 9258 Wealth Management LLC now owns 2,915 shares of the medical research company’s stock valued at $674,000 after buying an additional 770 shares during the period. Vestmark Advisory Solutions Inc. bought a new stake in IQVIA in the fourth quarter worth $542,000. Metis Global Partners LLC boosted its stake in IQVIA by 4.2% during the fourth quarter. Metis Global Partners LLC now owns 8,258 shares of the medical research company’s stock worth $1,911,000 after buying an additional 331 shares during the period. Finally, Spire Wealth Management increased its position in IQVIA by 9.1% during the fourth quarter. Spire Wealth Management now owns 1,016 shares of the medical research company’s stock valued at $219,000 after acquiring an additional 85 shares during the last quarter. 89.62% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other IQVIA news, insider Eric Sherbet sold 1,300 shares of IQVIA stock in a transaction on Tuesday, August 27th. The shares were sold at an average price of $246.33, for a total value of $320,229.00. Following the transaction, the insider now directly owns 19,536 shares of the company’s stock, valued at $4,812,302.88. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 1.60% of the stock is currently owned by company insiders.

IQVIA Stock Up 0.4 %

NYSE:IQV traded up $0.98 during trading hours on Wednesday, reaching $249.79. The company’s stock had a trading volume of 251,700 shares, compared to its average volume of 1,054,263. The company has a debt-to-equity ratio of 1.80, a quick ratio of 0.85 and a current ratio of 0.85. The company has a market capitalization of $45.54 billion, a P/E ratio of 33.98, a price-to-earnings-growth ratio of 2.37 and a beta of 1.49. The stock has a 50 day moving average price of $232.82 and a two-hundred day moving average price of $234.41. IQVIA Holdings Inc. has a 12 month low of $167.42 and a 12 month high of $261.73.

IQVIA (NYSE:IQV) last posted its earnings results on Monday, July 22nd. The medical research company reported $2.64 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.57 by $0.07. The company had revenue of $3.81 billion for the quarter, compared to analyst estimates of $3.79 billion. IQVIA had a return on equity of 28.59% and a net margin of 9.39%. The firm’s quarterly revenue was up 2.3% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.22 earnings per share. Equities analysts predict that IQVIA Holdings Inc. will post 10.24 EPS for the current fiscal year.

Analyst Ratings Changes

IQV has been the subject of a number of recent analyst reports. StockNews.com cut shares of IQVIA from a “buy” rating to a “hold” rating in a research note on Tuesday, August 27th. The Goldman Sachs Group began coverage on IQVIA in a research note on Thursday, June 6th. They set a “buy” rating and a $270.00 target price on the stock. Morgan Stanley boosted their price objective on IQVIA from $270.00 to $280.00 and gave the company an “overweight” rating in a report on Tuesday, July 23rd. UBS Group increased their target price on IQVIA from $295.00 to $300.00 and gave the stock a “buy” rating in a research note on Tuesday, July 23rd. Finally, Robert W. Baird boosted their target price on shares of IQVIA from $235.00 to $251.00 and gave the company a “neutral” rating in a research note on Tuesday, July 23rd. Five investment analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, IQVIA currently has a consensus rating of “Moderate Buy” and an average target price of $266.25.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.